Barclays raises Sotera Health stock price target to $17 from $13

Barclays has raised its price target on Sotera Health (SHC) to $17.00 from $13.00, while maintaining an Overweight rating, citing an updated valuation assessment and the belief that SHC's core business remains undervalued. This revision implies an 11x EV/EBITDA multiple based on Barclays' 2026 EBITDA estimate, despite ongoing litigation concerns that cap investor sentiment. Concurrently, Sotera Health reported robust Q2 2025 financial results, with adjusted EPS of $0.20 and revenue of $294.34 million, both significantly surpassing analyst expectations, which contributed to positive investor sentiment.

Analysis

Barclays has significantly upgraded its valuation for Sotera Health (SHC), raising the price target to $17.00 from $13.00 while reiterating an Overweight rating. This revision is underpinned by a new valuation model applying an 11x EV/EBITDA multiple to a 2026 EBITDA estimate of $618 million, an increase from the previous 9.2x multiple on a $610 million estimate. This bullish analyst stance is supported by Sotera's robust Q2 2025 financial performance, where the company surpassed expectations with an adjusted EPS of $0.20 against a $0.17 forecast and revenue of $294.34 million versus a $275.89 million estimate. Despite these strong fundamentals and a subsequent surge in positive sentiment, Barclays acknowledges that ongoing litigation concerns remain a significant overhang, actively capping investor willingness to award the stock a premium valuation. The core investment thesis balances the company's demonstrated operational strength and undervalued core business against this persistent legal risk.

Key Decisions for Investors

• Investors may consider the substantial earnings beat and Barclays' price target increase as validation of the company's fundamental strength, potentially justifying a long position despite acknowledged risks.
• It is critical to closely monitor developments in the ongoing litigation, as this is identified as the primary factor suppressing the stock's valuation and any resolution, positive or negative, will likely be a major catalyst.
• Consider the valuation conflict between Barclays' bullish 11x EV/EBITDA target and the current market sentiment, as the litigation overhang may continue to cap near-term share price appreciation until there is greater legal clarity.